Ebinger Joseph E, Driver Matthew, Ouyang David, Botting Patrick, Ji Hongwei, Rashid Mohamad A, Blyler Ciantel A, Bello Natalie A, Rader Florian, Niiranen Teemu J, Albert Christine M, Cheng Susan
Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
EClinicalMedicine. 2022 May 13;48:101442. doi: 10.1016/j.eclinm.2022.101442. eCollection 2022 Jun.
Individual-level blood pressure (BP) variability, independent of mean BP levels, has been associated with increased risk for cardiovascular events in cohort studies and clinical trials using standardized BP measurements. The extent to which BP variability relates to cardiovascular risk in the real-world clinical practice setting is unclear. We sought to determine if BP variability in clinical practice is associated with adverse cardiovascular outcomes using clinically generated data from the electronic health record (EHR).
We identified 42,482 patients followed continuously at a single academic medical center in Southern California between 2013 and 2019 and calculated their systolic and diastolic BP variability independent of the mean (VIM) over the first 3 years of the study period. We then performed multivariable Cox proportional hazards regression to examine the association between VIM and both composite and individual outcomes of interest (incident myocardial infarction, heart failure, stroke, and death).
Both systolic (HR, 95% CI 1.22, 1.17-1.28) and diastolic VIM (1.24, 1.19-1.30) were positively associated with the composite outcome, as well as all individual outcome measures. These findings were robust to stratification by age, sex and clinical comorbidities. In sensitivity analyses using a time-shifted follow-up period, VIM remained significantly associated with the composite outcome for both systolic (1.15, 1.11-1.20) and diastolic (1.18, 1.13-1.22) values.
VIM derived from clinically generated data remains associated with adverse cardiovascular outcomes and represents a risk marker beyond mean BP, including in important demographic and clinical subgroups. The demonstrated prognostic ability of VIM derived from non-standardized BP readings indicates the utility of this measure for risk stratification in a real-world practice setting, although residual confounding from unmeasured variables cannot be excluded.
This study was funded in part by National Institutes of Health grants R01-HL134168, R01-HL131532, R01-HL143227, R01-HL142983, U54-AG065141; R01-HL153382, K23-HL136853, K23-HL153888, and K99-HL157421; China Scholarship Council grant 201806260086; Academy of Finland (Grant no: 321351); Emil Aaltonen Foundation; Finnish Foundation for Cardiovascular Research.
在队列研究和使用标准化血压测量的临床试验中,个体水平的血压(BP)变异性独立于平均血压水平,已被证明与心血管事件风险增加相关。在现实世界的临床实践环境中,血压变异性与心血管风险的关联程度尚不清楚。我们试图通过电子健康记录(EHR)中的临床生成数据,确定临床实践中的血压变异性是否与不良心血管结局相关。
我们识别出2013年至2019年间在南加州的一个学术医疗中心持续接受随访的42482名患者,并计算了他们在研究期前3年中独立于均值的收缩压和舒张压变异性(VIM)。然后,我们进行多变量Cox比例风险回归,以检验VIM与感兴趣的复合结局和个体结局(新发心肌梗死、心力衰竭、中风和死亡)之间的关联。
收缩压(HR,95%CI 1.22,1.17 - 1.28)和舒张压VIM(1.24,1.19 - 1.30)均与复合结局以及所有个体结局指标呈正相关。这些发现对于按年龄、性别和临床合并症进行分层具有稳健性。在使用时间推移随访期的敏感性分析中,收缩压(1.15,1.11 - 1.20)和舒张压(1.18,1.13 - 1.22)的VIM值仍与复合结局显著相关。
从临床生成数据得出的VIM仍然与不良心血管结局相关,并且代表了除平均血压之外的一个风险标志物,包括在重要的人口统计学和临床亚组中。从非标准化血压读数得出的VIM所显示的预后能力表明了该指标在现实世界实践环境中进行风险分层的效用,尽管无法排除未测量变量的残余混杂因素。
本研究部分由美国国立卫生研究院的R01 - HL134168、R01 - HL131532、R01 - HL143227、R01 - HL142983、U54 - AG065141;R01 - HL153382、K23 - HL136853、K23 - HL153888和K99 - HL157421基金资助;中国国家留学基金委201806260086号资助;芬兰科学院(资助编号:321351);埃米尔·阿尔托宁基金会;芬兰心血管研究基金会资助。